Why the FDA need TLT-Ruvidar...All the long on this board know why, but for the new people on this board, below is a good reason to hold on to your TLT shares.
Keytruda,CG007, Immunity Bio(Anktiva N803+BCG)....
In a video by Dr.McFarland (March 2,2024), Dr.McFarland said '' The above are all continous treatments, they are not a one time treatment(unlike TLT-Ruvidar 1-2 treatments), you have to take the above treatments for as long as you can tolerate them''.
Adstiladrin.
Adstiladrin has a 23%CR at 15 months(TLT-Ruvidar 40%CR optimized).
Adstiladrin can not treat immunodeficients patients.
In this link...
https://drugs.com/drug-interactions/nadofaragene-firadenovec,adstiladrin.html Adstiladrin has 285 major drugs interactions(that is huge).
-TLT-Ruvidar has a 40%CR at 15 months(optimized).
-TLT-Ruvidar will treat immunodeficients patients.
-TLT-Ruvidar has no major drugs interactions.
-TLT-Ruvidar is 100% safe(no restrictions).
In short TLT-Ruvidar is a 1-2 time treatment that will treat patients that nobody else can treat.
The above is why the FDA need TLT-Ruvidar, and why you should hold on to your TLT shares.